Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Conditioning

Conditioning

12

Pipeline Programs↗

14

Active Trials↗

10

Companies Involved↗

Conditioning is an emerging landscape with 12 programs across 10 companies. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

78/100

Attrition Rate

11/100

Pipeline

Programs by Phase

Preclinical3

Exendin-(9-39)

Eiger BioPharmaceuticals

Adept

University Hospital, Gasthuisberg

Vit C

Medical University of Vienna

Phase 1

No programs

Phase 26

Fludarabine; Melphalan; Busulfan

Ruijin Hospital

Venetoclax

AbbVie

Ruxolitinib

Incyte

Tacrolimus

Veloxis Pharmaceuticals

Bendamustine Hydrochloride

SymBio Pharmaceuticals

Phase 33

Melphalan

Apotex Inc.

Cyclophosphamide

Baxter Healthcare Corporation

Mycophenolate Mofetil

Roche

Approved

No programs

Analysis

Trial Status

74

clinical trials

Completed28 · 38%

Unknown status24 · 32%

Recruiting8 · 11%

Terminated7 · 9%

Not yet recruiting5 · 7%

Active, not recruiting1 · 1%

Other1 · 1%

Clinical Trials

Trial Activity

74 trials

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT06477549·220 enrolled

Two Step Haplo With Radiation Conditioning

Recruiting·TThomas Jefferson University·Phase 2·NCT05031897·63 enrolled

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT06199427·100 enrolled

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06557161·170 enrolled

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06564545·276 enrolled

Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT06829472·120 enrolled

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Recruiting·NNavy General Hospital, Beijing·Phase 1/2·NCT06471946·54 enrolled

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Recruiting·—·Phase 1/2·NCT03311503·12 enrolled

Taxi STEP (Social Networks, Technology, and Exercise Through Pedometers)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT03010163·290 enrolled

Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06758726·20 enrolled

Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

Not yet recruiting·IInstitut Paoli-Calmettes·Phase 2·NCT04451200·82 enrolled

Modified Conditioning Regimen for CML-BP

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07259161·40 enrolled

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Not yet recruiting·—·Phase 2·NCT06238245·22 enrolled

Reduced Intensity Conditioning for MDS

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07085156·45 enrolled

Comparison of Knowledge Levels of Regular Conditioning Workers With and Without a History of Injury Regarding Sports Anxiety, Sports Injury Anxiety, and Factors Causing Injury in Sports

Completed·IIstanbul Saglik Bilimleri University·N/A·NCT07259096·114 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)